Aptar Pharma Presents Webinar on USP <382>-Aligned Testing to Gain Earlier Insights into Injectable Systems
Aptar Pharma will host a live educational webinar entitled “How Early System-Level Evidence Can De-Risk Injectable Development”.
Join this webinar on:
October 27, 2026
9:00 AM London / 5:00 PM Beijing
OR
October 27, 2026
3:00 PM London / 10:00 AM New York
This webinar explores how earlier system-level evidence can help reduce risk in injectable development. Hosted by Pavan Hemmege, Technical Product Manager Injectables at Aptar Pharma, and Sara Masucci, Product Manager Syringe Platform at Stevanato Group, the session examines how USP <382>-aligned testing of representative prefilled syringe configurations can provide earlier insights into component interactions and support more informed delivery-system decisions.
Why attend?
Injectable container closure systems are often assessed component by component, across different suppliers. This can make it difficult for drug manufacturers to build an early, complete view of assembled-system performance. As development teams make delivery-system decisions before the formulation, device and validation strategy is fully defined, late-emerging system sensitivities can lead to additional investigation, repeated work or delays.
In this live webinar, experts from Aptar Pharma and Stevanato Group will share a practical approach to building useful assembled-system evidence earlier. Drawing on their joint work with representative prefilled syringe configurations, they will show how USP <382>-aligned functional testing can help injectable development teams understand component interactions before formal, drug-specific validation begins.
Participants may submit questions throughout, with speakers addressing them during the discussion and live Q&A.
What Participants Will Learn
- Where USP <382>-aligned system-level testing fits in early injectable development.
- What functional, sealing and container closure integrity data can reveal across representative PFS configurations.
- How comparative findings can help teams prioritize next technical questions before formal product-specific studies.
Who Should Attend
Professionals responsible for injectable development, CMC, R&D, quality, regulatory affairs, device and combination product development, technical operations and procurement. The session is designed for subject matter experts as well as directors and senior leaders responsible for development risk and timelines.